Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study
Covered in this story
Call it yourself
No calls on $ASH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ashland →Dalsna Finance is currently tracking 5 stories mentioning Ashland, the earliest published 4 Nov 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.